Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Sarepta Therapeutics鈥� SEC disclosures often means sifting through pages on exon skipping science, gene therapy batch yields, and multi-year cash burn tables. If you鈥檝e ever typed 鈥淪arepta Therapeutics SEC filings explained simply鈥� into a search bar, you already know the challenge. Stock Titan鈥檚 AI tackles that complexity head-on, turning dense research updates into plain-English highlights that focus on Duchenne muscular dystrophy trials, FDA milestones, and collaboration revenue streams.
Need the numbers fast? Our platform pulls every 鈥淪arepta Therapeutics quarterly earnings report 10-Q filing鈥� as soon as it hits EDGAR and pairs it with instant ratio analysis. AG真人官方-time alerts for 鈥淪arepta Therapeutics Form 4 insider transactions real-time鈥� let you see when directors buy ahead of pivotal readouts. Use AI-powered summaries to move from headline to detail across all major forms:
- Sarepta Therapeutics annual report 10-K simplified鈥攃ash runway, pipeline probability tables, and manufacturing capacity.
- Sarepta Therapeutics proxy statement executive compensation鈥攃ompare leadership incentives to clinical milestones.
- Sarepta Therapeutics 8-K material events explained鈥擣DA decisions, partnership payments, or safety updates within minutes.
The result: one page that answers the questions investors actually ask鈥斺�淗ow did Exondys 51 sales shift this quarter?鈥� or 鈥淲hat do Sarepta Therapeutics insider trading Form 4 transactions signal ahead of an FDA advisory meeting?鈥� Whether you鈥檙e tracking 鈥淪arepta Therapeutics executive stock transactions Form 4鈥� or need a deep 鈥淪arepta Therapeutics earnings report filing analysis,鈥� our AI shows you the story behind the numbers. Start 鈥渦nderstanding Sarepta Therapeutics SEC documents with AI鈥� today and make faster calls on gene-therapy breakthroughs without reading hundreds of pages first.
D. E. Shaw & Co., L.P. and founder David E. Shaw filed Amendment No. 1 to Schedule 13G disclosing a passive 5.1 % holding (5,059,912 shares) in Sarepta Therapeutics (SRPT) as of 18 Jul 2025. The stake is spread across three internal vehicles: D. E. Shaw Valence Portfolios (2.78 m shares), D. E. Shaw Oculus Portfolios (1.39 m) and accounts managed by D. E. Shaw Investment Management (0.89 m).
The reporting persons have shared voting power over 5,000,212 shares and shared dispositive power over the full 5,059,912 shares; they possess no sole voting or dispositive authority. The filing is made under Rule 13d-1(b) as an investment adviser and states the shares were not acquired to influence control of the issuer.
This amendment corrects the original 13G by attaching the Joint Filing Agreement dated 25 Jul 2025; no changes to ownership levels or intent are reported.
Veru Inc. (VERU) filed an 8-K disclosing results from its 25 July 2025 special shareholder meeting.
- Reverse stock split: Shareholders approved an amendment authorising the Board to implement a reverse split at any ratio between 1-for-2 and 1-for-20. Votes: 98,869,209 FOR, 7,080,957 AGAINST, 1,013,920 ABSTAIN; 0 broker non-votes.
- Adjournment proposal: Also approved with 100,083,638 FOR, 6,212,862 AGAINST, 667,586 ABSTAIN.
Out of 146,583,920 eligible shares, about 106.9 million (鈮�73%) were voted. No other matters were considered.
FAQ
What is the current stock price of Sarepta Therapeutics (SRPT)?
What is the market cap of Sarepta Therapeutics (SRPT)?
What is the core focus of Sarepta Therapeutics?
How does Sarepta approach drug development?
What therapeutic areas does Sarepta primarily target?
How does Sarepta differentiate itself in the competitive biotechnology landscape?
What role do strategic partnerships play for Sarepta?
How mature are Sarepta's product candidates?
What technologies underpin Sarepta's therapeutic approach?
How does Sarepta ensure the safety and efficacy of its therapies?
